3 completed, 2 withdrawn. 2 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Excessive Daytime Somnolence: new trials by email Literature Review of Excessive Daytime Somnolence trials Research Report on Excessive Daytime Somnolence
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study Valiloxybate, Placebo - Parkinson Disease, Excessive Daytime Somnolence | Phase 2 | Withdrawn | XWPharma | 2021-11-01 | 2025-03-19 | |
| Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration Solriamfetol 150 mg Oral Tablet - Narcolepsy, Obstructive Sleep Apnea | Phase 1 | Completed | Axsome Therapeutics, Inc. | 6 | 2021-08-27 | 2023-04-14 |
| An Open Label Study of FT218 in Subjects With Narcolepsy FT218 - Narcolepsy, Cataplexy | Phase 3 | Completed | Avadel | 184 | 2020-06-12 | 2025-10-02 |
| Start Times and Restful Sleep Delayed School Start Time - Excessive Daytime Somnolence, Sleep Deprivation | Withdrawn | University of California, San Diego | 2019-09-01 | 2020-07-15 | ||
| Caffeine for Excessive Daytime Somnolence in Parkinson's Disease Caffeine 100-200 mg BID, placebo - Parkinson's Disease, Excessive Daytime Somnolence | Phase 2 / Phase 3 | Completed | Ron Postuma | 58 | 2007-04-01 | 2015-04-16 |
Disorders of Excessive Somnolence (5) · Narcolepsy (2) · Parkinson Disease (2) · Cataplexy (1) · Parasomnias (1) · Sleep Apnea, Obstructive (1) · Sleep Deprivation (1) · Sleep Wake Disorders (1)
Dyssomnias (5) · Mental Disorders (5) · Nervous System Diseases (5) · Sleep Disorders, Intrinsic (5) · Sleep Wake Disorders (4) · Basal Ganglia Diseases (2) · Brain Diseases (2) · Central Nervous System Diseases (2) · Movement Disorders (2) · Neurodegenerative Diseases (2) · Neurologic Manifestations (2) · Parkinsonian Disorders (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Synucleinopathies (2)
BID protein, human (1) · Caffeine (1) · Tablets (1) · solriamfetol (1)
Avadel (1) · Axsome Therapeutics, Inc. (1) · Ron Postuma (1) · University of California, San Diego (1) · XWPharma (1)
United States (3) · Canada (2)
Daniel M. Canafax, PharmD (1) · Robert Owens, MD (1) · Ron Postuma, MD, MSc (1)